Fall 2026

Strategy & Execution Co-op

Prostate

Posted on 8/13/2026

Deadline 8/26/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

CA$23 - CA$33/hr

Toronto, ON, Canada

Remote

Bachelor's, PharmD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Data Visualization
Word/Pages/Docs
Version Control
Pharmacology
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Available to work for the duration of the 12-month co-op term.
  • Strong interest in pharmaceutical or biotechnology medical affairs, oncology, prostate cancer, scientific communications, or healthcare strategy.
  • Foundational understanding of clinical research, medical literature, and evidence-based scientific communication.
  • Proficiency with Microsoft Office applications, especially PowerPoint, Word, Excel, and Outlook.
  • Strong written and verbal communication skills.
  • Strong organizational skills, attention to detail, and ability to manage multiple priorities.
  • Ability to work independently and collaboratively in a cross-functional team environment.
  • Authorized to work in Canada on a full-time basis without the need for future sponsorship.
  • Remain actively enrolled in an academic program throughout the entire internship.
  • Available to work 37.5 hours during the entire internship.
  • Record of strong academic performance, with a recommended grade point average of 2.8 or above.
Responsibilities
  • Support execution of apalutamide medical affairs priorities, including prostate cancer scientific strategy, launch readiness, and cross-functional alignment.
  • Track, organize, and follow up on key deliverables across medical affairs workstreams.
  • Synthesize scientific and strategic information into concise summaries, trackers, and project updates for internal stakeholders.
  • Support development of materials that enable consistent scientific communication across internal teams and regional partners.
  • Capture meeting outputs and action items in meeting minutes for post-meeting distribution twice per month.
  • Assist with planning and execution of healthcare professional engagement activities, advisory boards, scientific exchange meetings, and related follow-up materials.
  • Prepare discussion guides, pre-read materials, insight-capture templates, and post-meeting summaries.
  • Organize and synthesize healthcare professional insights to inform medical strategy, content refinement, and future engagement planning.
  • Develop, refine, and format scientific slide decks, internal updates, and presentation materials.
  • Ensure consistency of scientific messaging, references, visual standards, and slide flow across materials.
  • Adapt complex scientific information into clear, concise formats for internal medical affairs audiences.
  • Collaborate with medical, agency, and cross-functional partners to incorporate feedback and maintain version control.
  • Support updates to scientific communication platform materials, including disease-state, product, and evidence-based content.
  • Organize references, review content for consistency, and maintain alignment across related communication resources.
  • Identify opportunities to improve the usability, clarity, and consistency of core scientific materials.
  • Contribute to internal tools and resources that help teams communicate scientific information consistently.
  • Develop and maintain frequently asked questions, objection handlers, and related medical communication resources.
  • Support One J&J voice deliverables by aligning content across internal stakeholders and ensuring consistent terminology, structure, and message flow.
  • Consolidate inputs from medical, regional, and cross-functional partners into clear draft materials for review.
  • Prepare concise response documents and internal summaries addressing anticipated scientific questions.
  • Support planning and execution activities for major oncology and urology congresses.
  • Assist with congress preparation materials, abstract and session tracking, competitive intelligence summaries, medical insights capture, and post-congress reports.
  • Prepare internal pre- and post-congress communication materials, including one-page summaries, slide updates, and key takeaways.
  • Coordinate congress-related deliverables across medical affairs and cross-functional teams.
  • Support social media and digital landscape analysis related to prostate cancer congresses, apalutamide, and relevant scientific topics.
  • Identify, organize, and summarize emerging themes, discussion trends, and scientific conversation topics from approved sources and tools.
  • Maintain scientific objectivity and avoid unsupported interpretation when summarizing external discussions.
  • Maintain project trackers, timelines, action logs, and meeting notes for assigned workstreams.
  • Coordinate with internal stakeholders to gather inputs, track feedback, and support completion of deliverables.
  • Handle scientific and business-sensitive information with professionalism, discretion, and accountability.
Desired Qualifications
  • PhD/PharmD candidate, graduate student, or recent graduate with academic experience in pharmacy, biomedical sciences, pharmacology, epidemiology, public health, medical sciences, or a related field.
  • Prior coursework, research, rotation, internship, or work experience in oncology, urology, medical affairs, clinical development, medical information, regulatory affairs, or medical communications.
  • Experience creating or refining slide decks, scientific summaries, or educational materials.
  • Familiarity with oncology terminology, clinical trial design, and common evidence-generation concepts.
  • Interest in prostate cancer, genitourinary oncology, launch readiness, congress strategy, or scientific communications.
  • Comfort working with digital tools, dashboards, social listening outputs, or structured trackers.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance increased.
  • Tremfya sales jumped 72.5% in Q2 2026, offsetting Stelara's biosimilar decline.
  • Rybrevant received FDA Priority Review August 2026 for head and neck cancer.

What critics are saying

  • The talc MDL still exceeded 63,000 claims in April 2026, and appeals continue.
  • J&J's $5.5 billion talc settlement covers existing ovarian cancer claims only, not future lawsuits.
  • Stelara sales fell 55% in Q2 2026, exposing pipeline execution pressure before 2027.

What makes Johnson & Johnson unique

  • J&J combines blockbuster drugs like Darzalex with MedTech breadth across hospitals and surgery.
  • IMAAVY gained FDA approval August 24, 2026, first therapy for warm autoimmune hemolytic anemia.
  • MONARCH QUEST 3 won FDA clearance August 17, 2026, advancing AI-guided bronchoscopy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 25th, 2026
Louisiana jury awards $10M in talc case, J&J liable for $1.2M amid broader settlement talks

A Louisiana jury awarded $10 million in a mesothelioma case linked to talc exposure, assigning Johnson & Johnson over $1.2 million of the liability. The jury found J&J's talc products unreasonably dangerous and inadequately labelled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson alongside a proposed $5.5 billion settlement aimed at resolving approximately 76,000 ovarian cancer claims. If the settlement proceeds with sufficient claimant participation, it could reduce legal uncertainty. Despite the legal challenges, Johnson & Johnson reported record quarterly sales supporting its Innovative Medicine and MedTech divisions. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth. Ongoing talc verdicts and potential follow-on cases continue to shape perceptions of the company's legal risk alongside its expanding medicines and MedTech portfolio.

PR Newswire
Aug 24th, 2026
FDA approves IMAAVY as first-ever treatment for warm autoimmune hemolytic anemia

The US Food and Drug Administration has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia in adults and children aged 12 and older. Johnson & Johnson announced the approval following FDA Priority Review. wAIHA is a rare, life-threatening condition where autoantibodies destroy red blood cells, causing severe anaemia and fatigue. Previously, only corticosteroids and immunosuppressants were available. The approval is based on the Phase 2/3 ENERGY study. Results showed approximately three times as many patients receiving IMAAVY achieved durable haemoglobin levels versus placebo by 24 weeks. Patients demonstrated a mean haemoglobin increase of 1 g/dL at Week 1. IMAAVY is an immunoselective FcRn blocker designed to reduce pathogenic IgG autoantibodies whilst preserving B-cell function. Common side effects included peripheral oedema, diarrhoea, and fever.

Yahoo Finance
Aug 24th, 2026
J&J rises 1.3% to $273 as investors seek stability amid tech selloff despite rich 32x earnings valuation

Johnson & Johnson shares rose approximately 1.2% to $273.31 on Monday as investors sought defensive stocks amid technology sector weakness. The pharmaceutical and medical-technology company reported second-quarter sales of $25.3 billion, up 6.6%, with adjusted earnings of $2.90 per share. The Innovative Medicine division posted 6.8% operational growth, whilst MedTech added 3.6%. Management raised its operating outlook, though acquisition-related costs affected reported profit guidance. However, the stock now trades at roughly 32 times earnings and sits 41.91% above its estimated fair value of $192.59. The company faces challenges including biosimilar competition for Stelara and uneven MedTech execution, with recent acquisitions expected to pressure near-term profits.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

INACTIVE